GLEEVEC vs RETEVMO

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 21, 2026·How we rate

Possible drug interaction. GLEEVEC and RETEVMO are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	GLEEVEC	RETEVMO
Rating	70/100	New
Pharmacy pays	~$25.80 /30	—
Type	RX	RX
Active ingredient	IMATINIB MESYLATE	SELPERCATINIB
Manufacturer	Novartis	Eli Lilly and Co
Dosage forms	Tablet	Capsule, Tablet
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	None	None
Treats	Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome	Non-Small-Cell Lung Carcinoma, Thyroid Neoplasms

gleevec retevmo

Rating

70/100

New

Pharmacy pays

~$25.80 /30

—

Type

Active ingredient

IMATINIB MESYLATE

SELPERCATINIB

Manufacturer

Novartis

Eli Lilly and Co

Dosage forms

Tablet

Capsule, Tablet

Drug class

Kinase Inhibitor

Boxed warning

None

Treats

Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome

Non-Small-Cell Lung Carcinoma, Thyroid Neoplasms

Frequently asked questions

What is the difference between Gleevec and Retevmo?

Gleevec contains Imatinib Mesylate, while Retevmo contains Selpercatinib — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.